6.38
5.45%
0.33
Dopo l'orario di chiusura:
6.45
0.07
+1.10%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VERV Giù?
Forum
Previsione
Precedente Chiudi:
$6.05
Aprire:
$6.19
Volume 24 ore:
1.56M
Relative Volume:
1.17
Capitalizzazione di mercato:
$539.90M
Reddito:
$20.65M
Utile/perdita netta:
$-192.65M
Rapporto P/E:
-2.0126
EPS:
-3.17
Flusso di cassa netto:
$-134.39M
1 W Prestazione:
+6.51%
1M Prestazione:
+27.60%
6M Prestazione:
-0.47%
1 anno Prestazione:
-59.05%
Verve Therapeutics Inc Stock (VERV) Company Profile
Nome
Verve Therapeutics Inc
Settore
Industria
Telefono
(978) 501-3026
Indirizzo
201 BROOKLINE AVENUE, BOSTON
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2023-04-13 | Iniziato | Canaccord Genuity | Buy |
2023-02-01 | Iniziato | Cantor Fitzgerald | Neutral |
2022-12-15 | Iniziato | Goldman | Sell |
2022-10-06 | Iniziato | Credit Suisse | Neutral |
2022-08-25 | Aggiornamento | Stifel | Hold → Buy |
2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
2022-02-18 | Iniziato | RBC Capital Mkts | Outperform |
2021-09-24 | Iniziato | Stifel | Hold |
2021-07-12 | Iniziato | Guggenheim | Buy |
2021-07-12 | Iniziato | JP Morgan | Neutral |
2021-07-12 | Iniziato | Jefferies | Buy |
2021-07-12 | Iniziato | William Blair | Outperform |
Mostra tutto
Verve Therapeutics Inc Borsa (VERV) Ultime notizie
Verve Therapeutics (NASDAQ:VERV) Trading Up 10.1%Here's What Happened - MarketBeat
Verve Therapeutics reports Q3 EPS (59c), consensus (70c) - TipRanks
Verve Therapeutics: Q3 Earnings Snapshot - Marketscreener.com
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Vanguard Group Inc's Strategic Reduction in Verve Therapeutics I - GuruFocus.com
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. - GuruFocus.com
Deadline coming up on Oct. 28th in Lawsuit for Investors who lost - openPR
Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - AccessWire
VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AccessWire
FINAL VERV DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Verve Therapeutics, Inc. Investors to Join the Class Action Lawsuit! - AccessWire
Verve Therapeutics, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before October 28, 2024 to Discuss Your RightsVERV - PR Newswire
VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, - GlobeNewswire
VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV - ForexTV.com
FINAL REMINDER VERV DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Verve Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit! - AccessWire
VERV Deadline: Rosen Law Firm Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV - Business Wire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc.VERV - cnhinews.com
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - PR Newswire
VERV DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV - GlobeNewswire Inc.
SHAREHOLDER ALERT: Holzer & Holzer, LLC Reminds Investors - GlobeNewswire
Verve Therapeutics (NASDAQ:VERV) Stock Price Up 7%Still a Buy? - MarketBeat
Verve Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 28, 2024 Deadline to file Lead Plaintiff Motion - ForexTV.com
Verve Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Verve Therapeutics stock plunges as cholesterol-lowering gene-editing treatment faces setback - MSN
Verve Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights – VERV - ForexTV.com
Verve Therapeutics Inc Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsVERV - PR Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - AccessWire
Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for InvestorsContact Levi & Korsinsky - AccessWire
VERV FINAL DEADLINE: RLF, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. - The Bakersfield Californian
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Investors in Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - AccessWire
Investors who Lost Money on Verve Therapeutics, Inc. (VERV) Should Contact Levi & Korsinsky About Pending Class ActionVERV - AccessWire
2024-10-21 | Investors in Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV | NDAQ:VERV | Press Release - Stockhouse Publishing
VERV Deadline: VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm - PR Newswire
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: - GlobeNewswire
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics, Inc. LawsuitVERV - AccessWire
2024-10-21 | Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics, Inc. LawsuitVERV | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - AccessWire
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineVERV - AccessWire
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - AccessWire
VERV DEADLINE: RLF, THE FIRST FILING FIRM, Encourages Verve - GlobeNewswire
How to Take Advantage of moves in (VERV) - Stock Traders Daily
Shareholders of Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - AccessWire
State Street Corp's Strategic Acquisition in Verve Therapeutics - Yahoo Finance
2024-10-16 | Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics Inc (VERV) looking to reclaim success with recent performance - SETE News
Verve Therapeutics Insider Purchases Yet To Pay Off Regardless Of Recent Strength - Simply Wall St
ROSEN, A TOP RANKED LAW FIRM, Encourages Verve - GlobeNewswire
Verve Therapeutics Inc Azioni (VERV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Verve Therapeutics Inc Azioni (VERV) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Ashe Andrew D. | See Remarks |
May 14 '24 |
Buy |
6.26 |
76,000 |
475,760 |
342,509 |
Nickerson Joan | Chief Administrative Officer |
Apr 02 '24 |
Sale |
8.24 |
1,514 |
12,475 |
8,659 |
Dorval Allison | Chief Financial Officer |
Nov 29 '23 |
Sale |
11.45 |
554 |
6,343 |
4,060 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):